| 000 | 01851 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517180938.0 | ||
| 264 | 0 | _c20180212 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1476-4687 | ||
| 024 | 7 |
_a10.1038/550174a _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCheck Hayden, Erika | |
| 245 | 0 | 0 |
_aThe rise and fall and rise again of 23andMe. _h[electronic resource] |
| 260 |
_bNature _c10 2017 |
||
| 300 |
_a174-177 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aBenzylisoquinolines _xtherapeutic use |
| 650 | 0 | 4 | _aBiosensing Techniques |
| 650 | 0 | 4 |
_aBloom Syndrome _xdiagnosis |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aDisclosure _xethics |
| 650 | 0 | 4 |
_aDrug Discovery _xmethods |
| 650 | 0 | 4 | _aFalse Positive Reactions |
| 650 | 0 | 4 |
_aGaucher Disease _xdrug therapy |
| 650 | 0 | 4 | _aGenes, BRCA1 |
| 650 | 0 | 4 | _aGenes, BRCA2 |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 |
_aGenetic Testing _xeconomics |
| 650 | 0 | 4 | _aGenome-Wide Association Study |
| 650 | 0 | 4 | _aHeredity |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIceland |
| 650 | 0 | 4 |
_aImmune System Diseases _xdrug therapy |
| 650 | 0 | 4 | _aInformation Dissemination |
| 650 | 0 | 4 |
_aNeoplasms _xdiagnosis |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSelf Report |
| 650 | 0 | 4 |
_aSkin Diseases _xdrug therapy |
| 650 | 0 | 4 | _aTranslational Research, Biomedical |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xlegislation & jurisprudence |
| 773 | 0 |
_tNature _gvol. 550 _gno. 7675 _gp. 174-177 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/550174a _zAvailable from publisher's website |
| 999 |
_c27675840 _d27675840 |
||